SCHEMBL932374

SCHEMBL932374

CSSC(C)(C)CCC(=O)N1CCN(C(=O)O)CC1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.36
LMNA P02545 2/20 0.36
KDM4E B2RXH2 1/20 0.36
MEN1 O00255 1/20 0.36
USP2 O75604 1/20 0.36
CYP3A4 P08684 1/20 0.36
HPGD P15428 1/20 0.36
KMT2A Q03164 1/20 0.36
HSD17B10 Q99714 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
HSD11B1 P28845 1/20 0.35
ATM Q13315 2/20 0.34
SMN1; SMN2 Q16637 1/20 0.33
TP53 P04637 1/20 0.33
ITGB3 P05106 2/20 0.33
ITGA2B P08514 2/20 0.33
NPC1 O15118 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
GNAI3 P08754 2/20 0.31
GNAI1 P63096 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL932406 0.84 GAA (0.43) ALDH1A1HPGDSMN1; SMN2ITGB3ITGA2B
Hydrochloric Acid SCHEMBL12079491 0.83 GAA (0.42) ALDH1A1HPGDSMN1; SMN2ITGB3ITGA2B
SCHEMBL12092257 0.82 DDB1 (0.43) MEN1USP2HPGDKMT2ASMN1; SMN2
SCHEMBL932864 0.77 PIK3CD (0.33) HSD11B1
SCHEMBL31651487 0.75 SIGMAR1 (0.63)
SCHEMBL932574 0.73 NAALAD2 (0.41) ALDH1A1LMNAMEN1CYP3A4KMT2A
SCHEMBL26127197 0.72 KDM4E (0.48) ALDH1A1LMNAKDM4EMEN1USP2
SCHEMBL1744332 0.71 SIGMAR1 (0.45) KDM4E
SCHEMBL18788632 0.70 GAA (0.45) ALDH1A1HPGDATMSMN1; SMN2ITGB3
SCHEMBL16472473 0.69 ALDH1A1 (0.39) ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8952147-B2 Conjugates, preparation thereof, and therapeutic use thereof SANOFI (FR) 2015-02-10 US disclosed
US-20120225089-A1 NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-09-06 US disclosed
EP-2448929-A1 NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-05-09 EP disclosed
WO-2011001052-A1 NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-01-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120225089-A1 NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF ERG28, CARS1, FOLH1 ALDH1A1 1912/4885LMNA 2220/4885KDM4E 4517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.